Literature DB >> 17135812

ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.

Mary Sano1, Carolyn W Zhu, Peter J Whitehouse, Steven Edland, Shelia Jin, Karin Ernstrom, Ronald G Thomas, Leon J Thal, Steven H Ferris.   

Abstract

BACKGROUND: The Prevention Instrument project of the Alzheimer's Disease Cooperative Study (ADCS) seeks to develop instruments to assess treatment efficacy including potential economic benefit. The Resource Use Inventory (RUI) is an instrument that has been used to capture resource utilization and costs in populations with Alzheimer disease (AD). However, resource utilization and costs for healthy, cognitively intact elderly as they begin to demonstrate cognitive deterioration are not well understood. In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented.
OBJECTIVES: To evaluate the utility of the RUI in a sample of cognitively intact elderly individuals living in the community and enrolled in AD prevention trials.
METHODS: The RUI was administered to 644 subjects and their study partners either at home or in the clinic. For half of each sample, 3-month retesting was carried out. The RUI consisted of 9 questions. The first part of the RUI captured subjects' use of direct medical care (eg, hospitalizations) and nonmedical care (eg, home health aides). The second part of the RUI captured the time caregivers spend providing care to the subjects. The third part of the RUI captured subjects' participation in volunteer work and employment. The assessment interval for each question was the past 3 months.
RESULTS: The percentage of RUI forms returned incomplete or inaccurate for both in-clinic and at-home groups was extremely low. There were no differences in utilization rates between in-clinic and at-home group for all items in the RUI. Except for use of outpatient procedures, tests, or treatments, there were no differences in utilization rates between subjects who filled out the RUI with the help of their study partners or by themselves. Items in the RUI were sensitive to subjects' cognitive and functional status and demographic characteristics.
CONCLUSIONS: Home-based completion of the RUI by participants in an AD prevention study is feasible, and seems to provide data that are reliable and valid. The instrument will be useful for tracking resource and time use through transition from healthy to cognitive impairment.

Entities:  

Mesh:

Year:  2006        PMID: 17135812      PMCID: PMC3229195          DOI: 10.1097/01.wad.0000213875.63171.87

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  15 in total

1.  Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.

Authors:  Howard Feldman; Serge Gauthier; Jane Hecker; Bruno Vellas; Birol Emir; Vera Mastey; Ponni Subbiah
Journal:  J Am Geriatr Soc       Date:  2003-06       Impact factor: 5.562

2.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

Review 3.  Galantamine: therapeutic effects beyond cognition.

Authors:  R Blesa
Journal:  Dement Geriatr Cogn Disord       Date:  2000-09       Impact factor: 2.959

4.  Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting.

Authors:  A Sicras; J Rejas; S Arco; E Flores; G Ortega; A Esparcia; A Suárez; M J Gordillo
Journal:  Dement Geriatr Cogn Disord       Date:  2005-03-22       Impact factor: 2.959

5.  Use of physician and acute care services by persons with and without Alzheimer's disease: a population-based comparison.

Authors:  C Leibson; T Owens; P O'Brien; S Waring; E Tangalos; V Hanson; M Plevak; E Kokmen
Journal:  J Am Geriatr Soc       Date:  1999-07       Impact factor: 5.562

6.  ADCS Prevention Instrument Project: overview and initial results.

Authors:  Steven H Ferris; Paul S Aisen; Jeffrey Cummings; Douglas Galasko; David P Salmon; Lon Schneider; Mary Sano; Peter J Whitehouse; Steven Edland; Leon J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Oct-Dec       Impact factor: 2.703

7.  Variation in cost of informal caregiving and formal-service use for people with Alzheimer's disease.

Authors:  Brooke S Harrow; Diane F Mahoney; Aaron B Mendelsohn; Marcia G Ory; David W Coon; Steven H Belle; Linda O Nichols
Journal:  Am J Alzheimers Dis Other Demen       Date:  2004 Sep-Oct       Impact factor: 2.035

8.  Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.

Authors:  E C Clipp; M J Moore
Journal:  Clin Pharmacol Ther       Date:  1995-08       Impact factor: 6.875

9.  Impact of donepezil treatment for Alzheimer's disease on caregiver time.

Authors:  Anders Wimo; Bengt Winblad; Sonali N Shah; Warren Chin; Richard Zhang; Thomas McRae
Journal:  Curr Med Res Opin       Date:  2004-08       Impact factor: 2.580

10.  The effects of galantamine treatment on caregiver time in Alzheimer's disease.

Authors:  Mary Sano; Gordon K Wilcock; Bart van Baelen; Shane Kavanagh
Journal:  Int J Geriatr Psychiatry       Date:  2003-10       Impact factor: 3.485

View more
  13 in total

1.  Protocol for an embedded pragmatic clinical trial to test the effectiveness of Aliviado Dementia Care in improving quality of life for persons living with dementia and their informal caregivers.

Authors:  Alycia A Bristol; Kimberly A Convery; Victor Sotelo; Catherine E Schneider; Shih-Yin Lin; Jason Fletcher; Randall Rupper; James E Galvin; Abraham A Brody
Journal:  Contemp Clin Trials       Date:  2020-04-19       Impact factor: 2.226

2.  Health-related resource use and costs in elderly adults with and without mild cognitive impairment.

Authors:  Carolyn W Zhu; Mary Sano; Steven H Ferris; Peter J Whitehouse; Marian B Patterson; Paul S Aisen
Journal:  J Am Geriatr Soc       Date:  2013-02-15       Impact factor: 5.562

3.  Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.

Authors:  Christopher M Callahan; Wanzhu Tu; Timothy E Stump; Daniel O Clark; Kathleen T Unroe; Hugh C Hendrie
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

4.  Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old.

Authors:  Mary Sano; Susan Egelko; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Michael Donohue; Sarah Walter; Shelly Sun; Luis Sauceda-Cerda
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

5.  Analysis of postdischarge costs following emergent general surgery in elderly patients.

Authors:  Gilgamesh J Eamer; Fiona Clement; Jenelle L Pederson; Thomas A Churchill; Rachel G Khadaroo
Journal:  Can J Surg       Date:  2018-02       Impact factor: 2.089

6.  The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Authors:  Clara Li; Judith Neugroschl; Xiaodong Luo; Carolyn Zhu; Paul Aisen; Steven Ferris; Mary Sano
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Developing dementia prevention trials: baseline report of the Home-Based Assessment study.

Authors:  Mary Sano; Susan Egelko; Michael Donohue; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Chung-Kai Sun; Silvia Paparello; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

8.  Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study.

Authors:  Carolyn W Zhu; Mary Sano; Steven H Ferris; Peter J Whitehouse; Marian B Patterson; Douglas Galasko; Lon S Schneider; Paul S Aisen
Journal:  J Am Geriatr Soc       Date:  2014-05       Impact factor: 5.562

9.  Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

Authors:  Douglas Galasko; Joanne Bell; Jessica Y Mancuso; James W Kupiec; Marwan N Sabbagh; Christopher van Dyck; Ronald G Thomas; Paul S Aisen
Journal:  Neurology       Date:  2014-04-02       Impact factor: 9.910

10.  Acute care utilization by dementia caregivers within urban primary care practices.

Authors:  Cathy C Schubert; Malaz Boustani; Christopher M Callahan; Anthony J Perkins; Siu Hui; Hugh C Hendrie
Journal:  J Gen Intern Med       Date:  2008-08-09       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.